To assess the distributionof serum concentrations of the atherogenic lipoprotein(a) [Lp(a)] in an obese population and the possible effects of weight reduction, we determined Lp(a) in 52 white, moderately obese subjects (16 men and 36 women). The subjects were participating in a weight-reduction program of diet, exercise, and behavior modification plus combination anorectic drug therapy (fenfluramine and phentermine). This placebo-controlled, double-blind study lasted 104 weeks. We also determined concentrations of fasting insulin, triglycerides, total cholesterol, high-density lipoprotein cholesterol, apolipoprotein (apo) A-I, low-density lipoproteincholesterol, and apo B. Results showed the following: a highly skewed, nongaussian distribution of serum Lp(a) values in the obese population, virtually identical to that reported for healthy adults; no clinicallysignificant change in Lp(a) concentrations with weight loss; and further evidence of normalization of insulin, lipid, and lipoprotein concentrations with weight loss. we undertook this study to determine whether weight loss in an obese population leads to a decrease in concentrations of serum Lp(a).
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Materials and Methods

Subjects and Experimental Design
Subjects were enrolled in a weight-reduction program, described in detail elsewhere (13,14) . Briefly, this double-blind study had three phases, each including diet, exercise, and behavior modification, with clinical and laboratory assessments after each phase (designated here as assessments 1, 2, and 3). The first phase was a six-week run-in period. In the second phase, 28 weeks (period 1), the subjects were randomly assigned to either a combination anorectic drug group (15) with the same drugs. Subjects were 130%-180% of normal body weight; subjects with hypertension or diabetes or taking prescription medication were excluded. Of the 121 subjects enrolled in the program, we report the results for the 52 for whom data were complete for all three assessment phases. The placebo and active treatment groups closely resembled the parent group in age and sex distribution, with eight men and 18 women in each of the two groups, ages 27 to 59 years; all subjects were white. Table 3 gives the correlation coefficients between BMI and each of the analytes except Lp(a) for both groups at each assessment. The marked decrease in insulin over period 2 is consistent not only with the substantial weight reduction, but also with the reported independent effect of fenfluramine on reducing insulin concentrations (19)-although this is controversial (22) .
Additionally, the correlation coefficients of insulin with BMI for each assessment (Table 3) in serum are reported to decrease with weight reduction. However, one study of obese, nondiabetic subjects on caloric restriction for weight reduction reported an early decrease in total and LDL cholesterol, followed later in the protocol by values essentially the same as the initial values. The data from our study appear consistent with that report. Concentrations of serum triglyceride (21, (23) (24) (25) (26) (28) (29) (30) (31) (32) (33) and apo B (27,30, 32, 34) reportedly decrease with weight reduction, as also was seen here. Table 1 and Figure 1 show statistically significant decreases in total cholesterol, LDL cholesterol, and ape B, and a statistically nonsignificant decrease in triglyceride in the placebo group over period 2. These results are consistent with the results of weight-reduction protocols involving fenfluramine (35, 36). Table 1 and Figure 1 indicate a statistically significant increase in HDL cholesterol and statistically nonsignificant minimal increase in serum apo A-I in the placebo group over period 1. The results for HDL cholesterol are consistent with many previous studies (20, 24, [26] [27] [28] [29] [30] [31] [32] [33] showing increases in serum HDL cholesterol with weight reduction. Studies relating apo A-I concentrations to weight and weight reduction are somewhat more variable, for the most part reporting increases of ape A-I (28,32,34,37)
for lower weight, but at least one report each presents data for no change (26) and for a decrease in ape A-I (27) . Table 1 and Figure 1 reveal a statistically nonsignificant increase in HDL cholesterol, and a statistically significant decrease in ape A-I in the placebo group over period 2. The results for HDL cholesterol are consistent with a previous study of weight reduction with fenfluramine, which reported increased concentrations of HDL cholesterol (36); however, the same study reported no change in total ape A-I concentrations, which is in contrast to our findings of a statistically significant decrease. Differences in study design (e.g., fenfluramine at 60 mg/day in slow-release capsule for 12 weeks vs the present study dose of 60 mg/day in slow-release tablet plus phentermi.ne, 15 mg/day, for six months) may account for the nonconcordance. The decrease in concentrations of ape A-I seen in the placebo group over period 2 is most likely attributable to fenfluramine because the period 1 control with no fenfluraimne actually showed an increase, albeit a nonsignificant one. Table 3 Tables 1 and 2 and Figure 1 present essentially identical trends over period 1 for the drug-treated group and period 2 for the placebo group. This is not unexpected in view of the similarity of the two groups with regard to drug treatment; thus, discussion of the drug-treated group results over period 1 closely parallels that of the placebo group over period 2. Table 2 and Figure 1 show minimal weight gain in the drug-treated group over period 2, leading to clinical and (or) statistically nonsignificant changes in the analytes. Figure   2 shows the distribution histogram of the pooled Lp(a) values of both groups for assessment 1. The distribution is highly skewed and nonnormal, with highly skewed and nonnorinal (7, 9, 38, 39) . Indeed, the distribution variables of this study are very close to typical reported values (9) of 0.14, 0.08, 0.19, 0.35, and 0.48 gIL. As recently reviewed (7) , the major determinant of Lp(a) concentration (estimated to account for at least 40% of variability) is thought to be the apo(a) genetic locus, which determines the apo(a) isoform, the molecular mass of which is inversely correlated with the concentration of Lp(a). In Caucasians, the skewed nature of the distributions is thought to result from the frequent occurrence of apo(a) alleles associated with low Lp(a) concentrations and the rare occurrence of alleles associated with high concentrations. Tables 1 and 2 and Figure 1 demonstrate no statistically significant changes in mean Lp(a) concentration over either period for either group. In general, these collective data suggest no clinically relevant change in Lp(a) concentration with significant weight loss via either diet, exercise, or behavior modification or drug therapy. However, several of the subjects with the greatest Lp(a) concentrations had reductions in Lp(a) with weight loss, suggesting the need for further studies with greater numbers of obese subjects with abovenormal concentrations of Lp(a).
In summary, the important points of this study are: the highly skewed, nonnormal distribution of concentrations of serum Lp(a) in an obese population that is virtually identical to that reported for healthy adults; the lack of a clinically significant change in Lp(a) concentrations with weight loss; and further evidence demonstrating normalization of insulin, lipid, and lipoprotein concentrations with weight loss.
